Last Updated: September 25, 2026

CLINICAL TRIALS PROFILE FOR MIRDAMETINIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for mirdametinib

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03905148 ↗	Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors	Recruiting	SpringWorks Therapeutics	Phase 1/Phase 2	2019-05-01	This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
NCT03905148 ↗	Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors	Recruiting	SpringWorks Therapeutics, Inc.	Phase 1/Phase 2	2019-05-01	This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
NCT03905148 ↗	Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors	Recruiting	BeiGene	Phase 1/Phase 2	2019-05-01	This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
NCT03962543 ↗	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas	Recruiting	SpringWorks Therapeutics, Inc.	Phase 2	2019-09-06	This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
NCT04923126 ↗	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	SpringWorks Therapeutics, Inc.	Phase 1/Phase 2	2021-06-21	This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for mirdametinib

Condition Name

Chart
Table

Condition Name for mirdametinib
Intervention	Trials
HER2-negative Breast Cancer	1
Recurrent Small Lymphocytic Lymphoma	1
MAP2K1 Gene Mutation	1
Vascular Anomalies	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for mirdametinib
Intervention	Trials
Neurofibromatoses	3
Neoplasms	2
Neurofibromatosis 1	2
Neurofibroma	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for mirdametinib

Trials by Country

Map
Table

Trials by Country for mirdametinib
Location	Trials
United States	42
Australia	4
Canada	1
France	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for mirdametinib
Location	Trials
Ohio	3
New York	3
New Jersey	3
Texas	2
Maryland	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for mirdametinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for mirdametinib
Clinical Trial Phase	Trials
PHASE2	3
PHASE1	6
Phase 2	2
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for mirdametinib
Clinical Trial Phase	Trials
Recruiting	13
NOT_YET_RECRUITING	3
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mirdametinib

Sponsor Name

Chart
Table

Sponsor Name for mirdametinib
Sponsor	Trials
SpringWorks Therapeutics, Inc.	7
National Cancer Institute (NCI)	2
Memorial Sloan Kettering Cancer Center	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for mirdametinib
Sponsor	Trials
Other	13
Industry	9
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.